DEFEAT THE VIRUS
AT ITS ENTRY POINT
InvisiShield is formed by a team of leading scientists and clinicians from both academia and industry with the goal of preventing viral respiratory infections, such as COVID-19.
We focus on preventing airborne viral infections by neutralizing its causative virus at its primary entry point of infection in the nasal cavity.
Our proprietary technology platform can also be applied to other respiratory viruses, including influenza and RSV.
SARS-COV-2
97M
Cases
Deaths
1M
INFLUENZA A
29M
Illnesses / yr
Deaths / yr
35K
RSV
235K
Hospitalization / yr
Death / yr
35K
THE BEST DEFENSE IS A GOOD OFFENSE
Our lead product, IS101, is a COVID-19 intranasal preventive spray that provides instant protection and operates independently of a person’s vaccination or immune system status.
Once sprayed into the nostrils, IS101 electrostatically interacts with native mucin proteins in the nose, thereby coating the principal portal of viral entry with an “invisible shield”.
IS101 “captures and kills” all current and potential future SARS-CoV-2 variants. It has also been engineered with our proprietary technology to increase its retention time on respiratory mucosal surfaces to extend the duration of protection.
Designed as a preventative for daily topical use, IS101 provided at least 10 hours of protection against infection in mice exposed to the highest viral load tested.
